RELEASES
-
For further information contact:
Fred Iannotti
802-888-0085
fiannotti@planningsource.comIdentafi™ 3000 Profiled in July 16 FOX34 Lubbock TV Interview With OrCA Founder Dr. Larry Hamburg
Co-Anchor & Health Reporter Melinda Alvarado Examines Oral Cancer
LUBBOCK, July 16, 2009 — Trimira LLC's Identafi™ 3000 oral cancer detection device was featured in a Thursday, July 16 broadcast on FOX34 Lubbock, The TV interview with dentist Dr. Larry Hamburg was conducted by Co-Anchor & Health Reporter Melinda Alvarado. The FOX34 video is archived online at:
Oral Cancer a Silent Killer
http://www.myfoxlubbock.com/dpp/news/local/071609oralcancerDr. Hamburg is founder and president of The Oral Cancer Awareness Foundation (OrCA) and principal in Hudson Valley Dental Arts, PC, near Poughkeepsie, N.Y.
The Oral Cancer Awareness Foundation (OrCA)
http://www.oralcancerawareness.com/Identafi™ 3000 is the most powerful and accurate device for screening dental patients to reveal signs of oral cancer and pre-cancer. The device incorporates next-generation oral cancer-detection "multispectral" optical technology that is changing the screening and diagnostic landscape for dentists and doctors across the nation.
Identafi™ 3000
http://www.trimira.net/identafiIdentafi™ 3000 boasts a number of connections with Texas, starting with the fact that its triple-wavelength (multispectral) technology was developed by a team of research scientists at America's top-rated and largest cancer center, The University of Texas M.D. Anderson Cancer Center, in collaboration with Rice University, both in Houston, as well as British Columbia Cancer Research Centre in Vancouver, Canada.
Identafi™ 3000 is made by Houston-based Trimira LLC, which is venture capital-funded by Dallas cancer research philanthropist T. Boone Pickens, of oil and windfarming fame.
Identafi™ 3000 represents a quantum leap in the visualization of mucosal abnormalities, including oral cancer or premalignant dysplasia. The multispectral technology employed in Identafi™ 3000 not only is effective in screening oral cancers but also in diagnosing cervical, skin, gastrointestinal, and bladder cancers. Unlike other methods, Identafi™ 3000 empowers doctors and dentists to pinpoint biochemical and morphological changes in cells.
About TRIMIRA™ LLC
TRIMIRA™ LLC is a subsidiary of Remicalm LLC, a privately held medical device and optical imaging company. Other subsidiaries are working on screening and diagnostic devices for skin, cervical, gastrointestinal, and bladder cancers. Remicalm, as the parent company, has licensed exclusive use of certain of its patents and patents pending for use as a cervical cancer product to be later expanded to include additional epithelial-based cancers. Remicalm's core technologies are based on high-speed, high-resolution capabilities from its patented optical processing technology platforms and include the ability to read metabolic and physiologic differences in diseased and healthy tissue in the human body.
Visit TRIMIRA™ at: http://www.trimira.net/
Animations
Identafi® Technology
Identafi® 3000 ultra Process
Screening Results
Training
